Rakesh Nagilla - SK Life Science Labs , 2500 Renaissance Blvd , King of Prussia , Pennsylvania 19406 , United States

基本信息

浏览量：24

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 48 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Discovery and Characterization of a P300-Selective Degrader with Potent Anti-Tumor Activity in CBP Mutant Cancers

Mike R. Russell, Cassandra L. Lowenstein, Xuqing Zhang, Jeremy Roach, Jianing Song,Rakesh Nagilla,Nathan Kendsersky, Shreyas Joshi,Peter Orth,Matt Tudor,Qiaolin Deng,Clemente Aguilar-Bonavides,Elham Behshad, Sudeep Banjade,Zhihua Sui,Corey Strickland,Larry Jolivette,Helai P. Mohammad

Cancer Researchno. 6_Supplement (2024): 6043-6043

引用0浏览0引用

Potent and Orally Efficacious PROTAC Degraders of Estrogen Receptor Α (Erα)

Rohan K. Rej, Zhixiang Chen,Ranjan K. Acharyya,Dimin Wu,Biao Hu, Guozhang Xu,Rakesh Nagilla,Hoda Metwally,Yu Wang,Bo Wen,Duxin Sun,Longchuan Bai,Shaomeng Wang

Cancer Researchno. 6_Supplement (2024): 4510-4510

引用0浏览0引用

Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders

Zhenwu Li, Lalgudi S. Harikrishnan, Guozhang Xu,Debangshu Samanta, Jose C. Clemente,Lingying Leng, Wenbin Tu, Lin Yang,Liyue Huang,Mi Wang,Shaomeng Wang,Qiaolin Deng,Elham Behshad,Rakesh Nagilla,Peter Orth, Cory Rice,Corey Strickland,Helai P. Mohammad, E. Scott Priestley,Zhihua Sui

JOURNAL OF MEDICINAL CHEMISTRY (2024)

引用0浏览0WOS引用

Discovery of Oral SMARCA2 Degraders for the Treatment of SMARCA4 Mutant Tumors

Jose C. Clemente, Lal Harikrishnan, Steve Knight,Debangshu Samanta, Zhenwu Li,Rakesh Nagilla,Nathan Kendsersky, Shreyas Joshi,Peter Orth,Matt Tudor,Qiaolin Deng,Clemente Aguilar-Bonavides,Elham Behshad,Zhihua Sui,Corey Strickland,Larry J. Jolivette,Helai P. Mohammad

Cancer Researchno. 6_Supplement (2024): 6051-6051

引用1浏览0引用

Discovery and Characterization of PVTX-321, an Estrogen Receptor Heterobifunctional Degrader

Courtney G. Havens, Guozhang Xu, Cass Lowenstein,Debangshu Samanta,Brian Vidal,Elham Behshad,Rakesh Nagilla,Mike Russell,Peter Orth,Winston Wu,Larry Jolivette, Scott Priestley,Helai Mohammad,Zhihua Sui

Cancer Researchno. 6_Supplement (2024): 6047-6047

引用0浏览0引用

the Selective IKZF2 Molecular Glue Degrader, PVTX-405, Counters Treg Immune Suppression,shows Significant Tumor Growth Delay As Single Agent and Synergistic Response with Immune Checkpoint Therapies (Icts)

Harshil D. Dhruv,Donna McEachern,Longchuan Bai, Xuqing Zhang, Zhixiang Chen,Rakesh Nagilla,Elham Behshad, Bomie Han,Peter Orth, Rohan Rej,Paul Kirchhoff,Niu Shin,Larry Jolivette,Corey Strickland,Zhihua Sui, Scott Priestley,Shaomeng Wang,Helai Mohammad

Cancer Researchno. 6_Supplement (2024): 2656-2656

引用0浏览0引用

Abstract A052: Discovery and Characterization of a P300-Selective Degrader Demonstrates Potent Anti-Tumor Activity in Preclinical Models of Prostate Cancer

Mike Russell, Cassandra L Lowenstein, Xuqing Zhang, Jeremy Roach, Jianing Song,Rakesh Nagilla,Peter Orth,Matt Tudor,Qiaolin Deng,Zhihua Sui,Corey Strickland,Larry J Jolivette, E Scott Priestley,Helai P Mohammad

Molecular Cancer Therapeuticsno. 12_Supplement (2023)

引用0浏览0引用

Predictive Wild-Type RAS/BRAF and Pharmacogenetic Biomarkers Drive Selection of Metastatic Colorectal Cancer Patients Fit for Intensive First-Line FIr-C/FOx-C Schedule Adding Cetuximab to Triplet Chemotherapy

Mike Russell, Cassandra L. Lowenstein, Xuqing Zhang, Jeremy Roach, Jianing Song,Rakesh Nagilla,Peter Orth,Matt Tudor,Qiaolin Deng,Zhihua Sui,Corey Strickland,Larry J. Jolivette, E. Scott Priestley,Helai P. Mohammad

MOLECULAR CANCER THERAPEUTICSno. 12 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn